VNX-101
CD19+ leukemias and lymphomas
Phase 1/2Active
Key Facts
About Vironexis Biotherapeutics
Vironexis Biotherapeutics, founded in 2021, is developing a transformative platform for AAV-delivered T-cell immuno-gene therapy. The company's TransJoin™ platform is designed to create off-the-shelf, single-infusion therapies that engineer a patient's T cells in vivo to target and kill cancer cells, bypassing the need for complex ex vivo cell manufacturing. Its pipeline includes over ten preclinical programs targeting blood cancers, solid tumors, and cancer prevention, with its lead asset, VNX-101 for CD19+ leukemias and lymphomas, having received FDA IND clearance and multiple regulatory designations. The company is led by a founding team with deep expertise in gene therapy development and oncology.
View full company profile